基于下丘脑激素肽类似物的复发性去势抵抗性前列腺癌新疗法。
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.
作者信息
Schally Andrew V, Block Norman L, Rick Ferenc G
机构信息
Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125; Department of Pathology; Department of Medicine, Division of Hematology/Oncology; Department of Medicine, Division of Endocrinology; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
出版信息
Asian J Androl. 2015 Nov-Dec;17(6):925-8. doi: 10.4103/1008-682X.152819.
Abstract
It is a pleasure to contribute our presentation at the International Prostate Forum of the Annual Meeting of the American Urological Association (AUA) to this special issue of the Asian Journal of Andrology.
摘要
很高兴能将我们在美国泌尿外科学会（AUA）年会国际前列腺论坛上的报告投稿至《亚洲男科学杂志》的这一特刊。
相似文献
1
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.
Asian J Androl. 2015 Nov-Dec;17(6):925-8. doi: 10.4103/1008-682X.152819.
2
Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Int J Urol. 2012 Jul;19(7):594-601. doi: 10.1111/j.1442-2042.2012.02997.x. Epub 2012 Mar 14.
3
4
GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
Mol Cancer Ther. 2019 Oct;18(10):1811-1821. doi: 10.1158/1535-7163.MCT-18-1337. Epub 2019 Jul 24.
5
Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
J Urol. 1984 Jun;131(6):1110-2. doi: 10.1016/s0022-5347(17)50833-2.
6
Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int. 2007 Dec;16(92):243.
7
Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Oncology (Williston Park). 2018 Dec 17;32(12):599-602, 604-6.
8
[Treatment of carcinoma of the prostate with analogs of LHRH].
Rev Clin Esp. 1986 Nov;179(8):407-11.
9
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
J Urol. 2006 Aug;176(2):520-5. doi: 10.1016/j.juro.2006.03.057.
10
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Ann Acad Med Singap. 2015 Oct;44(10):397-405.
引用本文的文献
1
Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7.
Cell Death Discov. 2022 May 3;8(1):241. doi: 10.1038/s41420-022-00951-4.
2
Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions.
Molecules. 2021 Apr 12;26(8):2228. doi: 10.3390/molecules26082228.
3
Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Cancer Res. 2018 Jun 15;78(12):3147-3162. doi: 10.1158/0008-5472.CAN-17-3006. Epub 2018 Apr 26.
本文引用的文献
1
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
2
Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
Cell Cycle. 2014;13(17):2790-7. doi: 10.4161/15384101.2015.945879.
3
Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.
Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2.
4
Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
Oncotarget. 2014 Jun 30;5(12):4567-78. doi: 10.18632/oncotarget.2146.
5
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
World J Gastroenterol. 2014 May 28;20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102.
6
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Eur Urol. 2014 Dec;66(6):1101-8. doi: 10.1016/j.eururo.2013.12.063. Epub 2014 Jan 9.
7
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1084-9. doi: 10.1073/pnas.1323102111. Epub 2014 Jan 6.
8
Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
Eur Urol. 2014 Mar;65(3):565-73. doi: 10.1016/j.eururo.2013.10.032. Epub 2013 Nov 1.
9
Agonists of luteinizing hormone-releasing hormone in prostate cancer.
Expert Opin Pharmacother. 2013 Nov;14(16):2237-47. doi: 10.1517/14656566.2013.834328. Epub 2013 Aug 28.
10
Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Oncol Rep. 2013 Jul;30(1):413-8. doi: 10.3892/or.2013.2435. Epub 2013 Apr 29.
Zotero 插件